Dapagliflozin PCD Pharma Franchise Company
Cafoli Lifecare offers a large Dapagliflozin range of 21 tablet formulations, manufactured in WHO-GMP certified facilities. Distributors serving diabetology, cardiology and nephrology prescribers can secure district-wise monopoly franchise rights across this fast-growing SGLT2-inhibitor category with full promotional support.
What is Dapagliflozin?
Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor. It lowers blood glucose by blocking glucose reabsorption in the kidney so that excess glucose is excreted in the urine, and it has additional proven benefits in heart failure and chronic kidney disease. Reference: PubChem - Dapagliflozin.
Available Forms
The Cafoli Dapagliflozin portfolio spans oral Tablets as plain dapagliflozin and in fixed-dose combinations with metformin, vildagliptin, sitagliptin, linagliptin and glimepiride. Contact us for current pack presentations and combinations.
Therapeutic Applications
Dapagliflozin is prescribed for type-2 diabetes mellitus (alone or with other anti-diabetics), heart failure with reduced and preserved ejection fraction, and chronic kidney disease. Prescribers include diabetologists, endocrinologists, cardiologists, nephrologists and physicians.
Why Dapagliflozin is a High-Potential Molecule for Distributors
SGLT2 inhibitors are among the fastest-growing drug classes in India, propelled by a vast diabetic population and expanding cardiac and renal indications. With 21 formulations including the popular dapagliflozin-metformin and gliptin combinations, a distributor can capture a large share of chronic anti-diabetic prescribing that generates high-value lifelong refills.
Why Choose Cafoli Lifecare
Cafoli Lifecare offers monopoly franchise rights, WHO-GMP certified manufacturing, DCGI-approved formulations, a network of 1000+ franchise partners across India, and free promotional inputs.
References
- PubChem: Dapagliflozin
- MedlinePlus: Dapagliflozin
- PubMed: dapagliflozin in heart failure and CKD
Our formulations of Dapagliflozin find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: